Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

QResearch supports Europe’s largest adverse drug reaction detection project

EMIS : 20 March, 2008  (Company News)
The first large scale European-wide initiative to detect adverse drug reactions (ADRs) – the ALERT project is being supported by QResearch – a not-for-profit partnership between EMIS and the University of Nottingham.
The QResearch database, which houses anonymous data from around 10 million UK patients, is the largest and most rapidly updated database taking part in the project, which has received €5 million funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement No 215847.

The recently approved ALERT project aims to develop the first Europe-wide computerised system to detect ADRs better and faster than the current spontaneous reporting systems. The initial research phase is planned to span 3.5 years.

The project will involve a consortium of 18 leading European research institutions using clinical data from the electronic healthcare records (EHRs) of over 30 million patients from European countries including The Netherlands, Denmark, UK and Italy.

The interdisciplinary team of researchers will use biomedical informatics technologies to do this, combined with biological and molecular knowledge.

ALERT will use a variety of text mining, epidemiological and other computational techniques to analyse the EHRs to detect ‘signals’ (combinations of drugs and suspected adverse events that warrant further investigation).

QResearch project leader, professor Julia Hippisley-Cox of the University of Nottingham said: “ALERT will, for the first time, design, develop and set up a process for monitoring adverse drug reactions for a significant proportion of the European population.”

“We hope that the project will demonstrate that scientific and clinical evidence can quickly and directly be translated into improvements in Patient safety and therefore health benefits. It will also enable us to compare how different people respond to a variety of drugs throughout Europe.”

“Another benefit of the research will mean that we should be able to discriminate between true signals that point to an ADR and spurious signals. This can help to reduce uncertainty among both patients and physicians, ultimately saving lives and increasing the quality of day-to-day life for many patients.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo